Geron Corporation has announced a strategic restructuring plan aimed at positioning the company for long-term value creation and improved financial discipline. The restructuring will result in approximately a one-third reduction of its current workforce of about 260 employees and is expected to be substantially complete in the first quarter of 2026. Geron anticipates that its full year 2026 operating expenses will be lower than those projected for 2025, with savings beginning in early 2026. The company's key objectives remain focused on driving commercial growth for RYTELO in the U.S., expanding its availability internationally, and advancing the Phase 3 IMpactMF trial. Restructuring charges will primarily consist of cash-based expenses, with further details to be disclosed in a forthcoming SEC filing.